Data points to no age-related cutoff for mammogram screenings | RSNA 2016 Roundup

There is no clear cut-off age to stop breast cancer screening, according to new data from the largest-ever study on mammogram screening outcomes. Data from the study was presented this week at the Radiological Society of North America’s annual meeting. Age-based cutoffs for screenings have been a source of controversy for many years in the healthcare field. Results from the massive study, however, support guidelines that support making breast cancer screening decisions based on individual patients and health status over a specific age, according to study researchers. Data in the study came from over 5.6 million mammogram screenings performed over 7 years between January 2008 and December 2014 and across 150 facilities in 31 U.S. states. Patient demographic data, mammography and biopsy results were considered in the analysis, with over 2.5 million women over 40 in the study. A total of 4 standard performance metrics were used to evaluate the data at each age group, including cancer detection rate, recall rate, positive predictive value for biopsies and biopsies performed. The mean rate of cancer detection was clocked at 3.74 per 1,000 patients, with a recall rate of 10%, positive predictive value of recommended biopsies at 20% and for biopsies performed at 29%. In considering age between 40 and 80 years, metrics showed a gradualte upward trend in terms of cancer detection rate and biopsy prediction rate, but a downward trend in recall rate. “All prior randomized, c...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Imaging Oncology Radiological Society of North America Source Type: news

Related Links:

AbstractPurpose of the ReviewBrain metastasis is a common complication of advanced malignancies, especially, lung cancer, breast cancer, renal cell carcinoma, and melanoma. Traditionally surgery, when indicated, and radiation therapy, either as whole-brain radiation therapy or stereotactic radiosurgery, constituted the major treatment options for brain metastases. Until recently, most of the systemic chemotherapy agents had limited activity for brain metastases. However, with the advent of small molecule tyrosine kinase inhibitors and immunotherapy agents, there has been renewed interest in using these agents in the manage...
Source: Current Neurology and Neuroscience Reports - Category: Neuroscience Source Type: research
Triple-negative breast cancer (TNBC) is typically aggressive, difficult to treat, and commonly metastasizes to the visceral organs and soft tissues, including the lungs and the brain. Taxanes represent the most effective and widely used therapeutic class in metastatic TNBC but possess limiting adverse effects that often result in a delay, reduction, or cessation of their use. DZ-2384 is a candidate microtubule-targeting agent with a distinct mechanism of action and strong activity in several preclinical cancer models, with reduced toxicities. DZ-2384 is highly effective in patient-derived taxane-sensitive and taxane-resist...
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: Preclinical Reports Source Type: research
Genomics and Health Disparities Lecture Series John Carpten, PhD is Professor and Chair for the Department of Translational Genomics. His training and professional experiences include postdoctoral training at the National Human Genome Research Institute/NIH, and serving as Deputy Director of Research at the Translational Genomics Research Institute (TGen). Dr. Carpten ’ cancer research program spans multiple disciplines including germline genetics for disease risk and predisposition, somatic cancer genomics, health disparities research, cell biology, functional genomics, and precision medicine. The primary focus of h...
Source: Videocast - All Events - Category: General Medicine Tags: Upcoming Events Source Type: video
In the next 5-7 years, the bioprinting market is estimated to expand by 15.7 percent, and it is anticipated to grow over $4.70 billion by 2025, according to the latest study of BIS Research. While the growth statistics indicate a turbulent landscape, it is worth familiarizing with the main players. Here, we collected the best bioprinting companies currently on the market. The future of bioprinting: tissues not organs The idea of lab-grown organs might mean the end of testing drugs on animals or humans, the solution for organ shortages and an ending of the desperate state of organ donations worldwide. If the creators of the...
Source: The Medical Futurist - Category: Information Technology Authors: Tags: 3D Printing in Medicine Biotechnology Business Future of Medicine 3d printed bioprinting company Healthcare Innovation market regenerative skin Source Type: blogs
ConclusionMyocardial strain imaging has been able to predict pre-clinical changes in LV systolic function and GLS is an independent early predictor of subsequent reduction in EF in breast cancer patients treated with trastuzumab.
Source: Journal of Echocardiography - Category: Cardiology Source Type: research
ConclusionsThese results support assessments of precision medicine-guided targeting of autophagy in treatment of brain metastases in breast cancer patients.
Source: Journal of Neuro-Oncology - Category: Cancer & Oncology Source Type: research
Jade Goffin, 30, from London, thought she'd beaten a rare form of breast cancer after undergoing treatment. But she was heartbroken to find it then spread into her brain...
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
Conditions:   Metastatic Breast Cancer With HER2 Positive;   Triple Negative Breast Cancer Intervention:   Procedure: Brain MRI Sponsor:   Yonsei University Not yet recruiting
Source: - Category: Research Source Type: clinical trials
Abstract The treatment of intractable vasogenic brain edema (VBE) caused by tumor and irradiation is challenging. Traditional intervention strategy includes dehydration and glucocorticoids accompanied by obvious side effects and minor effects after long-term use. Novel treatment needs to be found urgently. Recently, vascular endothelial growth factor (VEGF)/VEGFR pathway has been revealed to be essential in VBE. Therefore, tyrosine kinase inhibitor (TKI) targeting VEGFR which blocks (VEGF)/VEGFR signal might be effective. However, such reports have seldom been described. Herein, we documented a heavily-treated bre...
Source: Cancer Biology and Therapy - Category: Cancer & Oncology Authors: Tags: Cancer Biol Ther Source Type: research
Conclusion: The tumor control following repeat SRS for locally recurring metastatic brain tumors after a previous SRS is relatively lower than that for primary SRS. However, both low tumor volume and high prescription radiation dose were significantly related to the tumor control following repeat SRS for these tumors after previous SRS, which is a general understanding of primary SRS for metastatic brain tumors. PMID: 30064202 [PubMed - as supplied by publisher]
Source: Journal of Korean Neurosurgical Society - Category: Neurosurgery Tags: J Korean Neurosurg Soc Source Type: research
More News: Angiography | Brain | Brain Cancers | Breast Cancer | Cancer | Cancer & Oncology | Cardiology | Databases & Libraries | Heart | Lung Transplant | Mammography | Neurology | Partnerships | Radiography | Study | Ultrasound | Women